U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H27N7O3S2
Molecular Weight 513.636
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PICTILISIB

SMILES

CS(=O)(=O)N1CCN(CC2=CC3=NC(=NC(N4CCOCC4)=C3S2)C5=CC=CC6=C5C=NN6)CC1

InChI

InChIKey=LHNIIDJUOCFXAP-UHFFFAOYSA-N
InChI=1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4,13-14H,5-12,15H2,1H3,(H,24,27)

HIDE SMILES / InChI

Molecular Formula C23H27N7O3S2
Molecular Weight 513.636
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Pictilisib is an oral potent inhibitor of class I PI3K with nanomolar activities against p110alpha, p110beta, p110delta, and p110gamma. The drug was developed for the treatment of solid tumors and reached phase II in patients with breast cancer and lung carcinoma, however its development was terminated.

CNS Activity

Curator's Comment: Experiments on mice revealed that pictilisib transport to brain is very limited.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
3.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39.
2010 Apr
Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.
2010 Nov 24
Role of P-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.
2010 Sep
Targeting a common collaborator in cancer development.
2010 Sep 8
PI3K inhibition enhances doxorubicin-induced apoptosis in sarcoma cells.
2012
Modulators of sensitivity and resistance to inhibition of PI3K identified in a pharmacogenomic screen of the NCI-60 human tumor cell line collection.
2012
The antitumor effect of GDC-0941 alone and in combination with rapamycin in breast cancer cells.
2012
Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels.
2012 Aug
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
2012 Dec 15
Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent.
2012 May
Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells.
2012 May 17
Regulation of CD38 expression in human airway smooth muscle cells: role of class I phosphatidylinositol 3 kinases.
2012 Oct
A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal.
2013 Feb 1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
2013 Nov
The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.
2014 Jan 16
Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs.
2015 Jun
Patents

Sample Use Guides

Patients with breast cancer receive paclitaxel (90 mg/m2 weekly for 3 weeks in every 28-day cycle) with 260 mg pictilisib (daily on days 1-5 every week).
Route of Administration: Oral
Human breast tumor cell lines were treated with GDC-0941 (dose range 0.083–5 mM) to test cell viability in vitro.
Substance Class Chemical
Created
by admin
on Fri Dec 15 21:13:30 GMT 2023
Edited
by admin
on Fri Dec 15 21:13:30 GMT 2023
Record UNII
ICY00EMP8P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PICTILISIB
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
Pictilisib [WHO-DD]
Common Name English
4-(2-(1H-INDAZOL-4-YL)-6-((4-(METHYLSULFONYL)PIPERAZIN-1-YL)METHYL)THIENO(3,2-D)PYRIMIDIN-4-YL)MORPHOLINE
Systematic Name English
PICTRELISIB
Common Name English
THIENO(3,2-D)PYRIMIDINE, 2-(1H-INDAZOL-4-YL)-6-((4-(METHYLSULFONYL)-1-PIPERAZINYL)METHYL)-4-(4-MORPHOLINYL)-
Systematic Name English
pictilisib [INN]
Common Name English
2-(1H-INDAZOL-4-YL)-6-((4-(METHANESULFONYL)PIPERAZIN-1-YL)METHYL)-4-(MORPHOLIN-4-YL)THIENO(3,2-D)PYRIMIDINE
Systematic Name English
PICTILISIB [MI]
Common Name English
CDC-0941
Code English
GDC 0941
Code English
GDC-0941
Code English
PICTILISIB [USAN]
Common Name English
Code System Code Type Description
EPA CompTox
DTXSID40241930
Created by admin on Fri Dec 15 21:13:30 GMT 2023 , Edited by admin on Fri Dec 15 21:13:30 GMT 2023
PRIMARY
DRUG BANK
DB11663
Created by admin on Fri Dec 15 21:13:30 GMT 2023 , Edited by admin on Fri Dec 15 21:13:30 GMT 2023
PRIMARY
FDA UNII
ICY00EMP8P
Created by admin on Fri Dec 15 21:13:30 GMT 2023 , Edited by admin on Fri Dec 15 21:13:30 GMT 2023
PRIMARY
INN
9417
Created by admin on Fri Dec 15 21:13:30 GMT 2023 , Edited by admin on Fri Dec 15 21:13:30 GMT 2023
PRIMARY
ChEMBL
CHEMBL521851
Created by admin on Fri Dec 15 21:13:30 GMT 2023 , Edited by admin on Fri Dec 15 21:13:30 GMT 2023
PRIMARY
SMS_ID
100000175029
Created by admin on Fri Dec 15 21:13:30 GMT 2023 , Edited by admin on Fri Dec 15 21:13:30 GMT 2023
PRIMARY
EVMPD
SUB120770
Created by admin on Fri Dec 15 21:13:30 GMT 2023 , Edited by admin on Fri Dec 15 21:13:30 GMT 2023
PRIMARY
MERCK INDEX
m11673
Created by admin on Fri Dec 15 21:13:30 GMT 2023 , Edited by admin on Fri Dec 15 21:13:30 GMT 2023
PRIMARY
CAS
957054-30-7
Created by admin on Fri Dec 15 21:13:30 GMT 2023 , Edited by admin on Fri Dec 15 21:13:30 GMT 2023
PRIMARY
NCI_THESAURUS
C165479
Created by admin on Fri Dec 15 21:13:30 GMT 2023 , Edited by admin on Fri Dec 15 21:13:30 GMT 2023
PRIMARY
PUBCHEM
17755052
Created by admin on Fri Dec 15 21:13:30 GMT 2023 , Edited by admin on Fri Dec 15 21:13:30 GMT 2023
PRIMARY
USAN
YY-114
Created by admin on Fri Dec 15 21:13:30 GMT 2023 , Edited by admin on Fri Dec 15 21:13:30 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY